The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 2, 2007, Pages

  Lenderink, Amanda M ^a   Liegel, Katharine ^a   Ljubanović, Danica ^b   Coleman, Kathrin E ^a   Gilkeson, Gary S ^c   Holers, V Michael ^a   Thurman, Joshua M ^a,d  

^a UNIVERSITY OF COLORADO   (United States)

^b University of Zagreb School of Medicine   (Croatia)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d B 115   (United States)

Author keywords

Proteinuria

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE ANTIBODY; DOXORUBICIN; ENZYME ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; GLOMERULOSCLEROSIS; GLOMERULUS; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY INTERSTITIUM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA;

EID: 34548381835     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00403.2006     Document Type: Article

References (41)

1. Alexopoulos E, Papaghianni A, Papadimitriou M. The pathogenetic significance of C5b-9 in IgA nephropathy. Nephrol Dial Transplant 10: 1166-1172, 1995.
2. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 168: 3601-3607, 2002.
3. Biancone L, David S, Della Pietra V, Montrucchio G, Cambi V, Camussi G. Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int 45: 451-460, 1994.
4. Biesecker G, Katz S, Koffler D. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med 154: 1779-1794, 1981.
5. Bohle A, Mackensen-Haen S, von Gise H. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol 7: 421-433, 1987.
6. Bohle A, Wehrmann M, Mackensen-Haen S, Gise H, Mickeler E, Xiao TC, Muller C, Muller GA. Pathogenesis of chronic renal failure in primary glomerulopathies. Nephrol Dial Transplant 9, Suppl 3: 4-12, 1994.
7. Camussi G, Rotunno M, Segoloni G, Brentjens JR, Andres GA. In vitro alternative pathway activation of complement by the brush border of proximal tubules of normal rat kidney. J Immunol 128: 1659-1663, 1982.
8. Camussi G, Stratta P, Mazzucco G, Gaido M, Tetta C, Castello R, Rotunno M, Vercellone A. In vivo localization of C3 on the brush border of proximal tubules of kidneys from nephrotic patients. Clin Nephrol 23: 134-141, 1985.
9. Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J Immunol 167: 5758 -5766, 2001.
10. Hori Y, Yamada K, Hanafusa N, Okuda T, Okada N, Miyata T, Couser WG, Kurokawa K, Fujita T, Nangaku M. Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria. Kidney Int 56: 2096-2106, 1999.
11. Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 14: S186-S191, 2003.
12. Ichida S, Yuzawa Y, Okada H, Yoshioka K, Matsuo S. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46: 89-96, 1994.
13. Kees-Folts D, Sadow JL, Schreiner GF. Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 45: 1697-1709, 1994.
14. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 61: 201-283, 1996.
15. Mackensen-Haen S, Bader R, Grund KE, Bohle A. Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin Nephrol 15: 167-171, 1981.
16. Matsumoto M, Fukuda W, Circolo A, Goellner J, Strauss-Schoenberger J, Wang X, Fujita S, Hidvegi T, Chaplin DD, Colten HR. Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci USA 94: 8720-8725, 1997.
17. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol 11: 700-707, 2000.
18. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 10: 2323-2331, 1999.
19. Nangaku M, Pippin J, Couser WG. C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys. J Am Soc Nephrol 13: 928-936, 2002.
20. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20: 1-17, 1992.
21. Nath KA, Hostetter MK, Hostetter TH. Increased ammoniagenesis as a determinant of progressive renal injury. Am J Kidney Dis 17: 654-657, 1991.
22. Nomura A, Morita Y, Maruyama S, Hotta N, Nadai M, Wang L, Hasegawa T, Matsuo S. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol 151: 539-547, 1997.
23. Peake PW, Pussell BA, Mackinnon B, Charlesworth JA. The effect of pH and nucleophiles on complement activation by human proximal tubular epithelial cells. Nephrol Dial Transplant 17: 745-752, 2002.
24. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, Holers VM. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med 188: 1321-1331, 1998.
25. Rangan GK, Pippin JW, Coombes JD, Couser WG. C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. Kidney Int 67: 492-503, 2005.
26. Remuzzi G. A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. Nephrol Dial Transplant 15, Suppl 6: 58-60, 2000.
27. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 51: 2-15, 1997.
28. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2: 363-366, 1968.
29. Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180: 35-48, 2001.
30. Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 110: 403-409, 1997.
31. Tang S, Leung JC, Abe K, Chan KW, Chan LY, Chan TM, Lai KN. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 111: 515-527, 2003.
32. Taube C, Thurman JM, Takeda K, Joetham A, Miyahara N, Carroll MC, Dakhama A, Giclas PC, Holers VM, Gelfand EW. Factor B of the alternative complement pathway regulates development of airway hyper-responsiveness and inflammation. Proc Natl Acad Sci USA 103: 8084-8089, 2006.
33. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 176: 1305-1310, 2006.
34. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 42: 87-97, 2005.
35. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 170: 1517-1523, 2003.
36. Thurman JM, Ljubanovic D, Royer PA, Kraus DM, Molina H, Barry NP, Proctor G, Levi M, Holers VM. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/ reperfusion. J Clin Invest 116: 357-368, 2006.
37. Thurman JM, Royer PA, Ljubanovic D, Dursun B, Lenderink AM, Edelstein C, Holers VM. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from the induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol 17: 707-715, 2006.
38. Turnberg D, Lewis M, Moss J, Xu Y, Botto M, Cook HT. Complement activation contributes to both glomerular and tubulointerstitial damage in adriamycin nephropathy in mice. J Immunol 177: 4094-4102, 2006.
39. Walport MJ. Complement. First of two parts. N Engl J Med 344: 1058-1066, 2001.
40. Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 58: 1797-1804, 2000.
41. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164: 786-794, 2000.